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Glycogen phosphorylase (GP) catalyzes the rate-
limiting step in glycogen catabolism and plays a
key role in maintaining cellular and organismal
glucose homeostasis. GP is the first protein whose
function was discovered to be regulated by revers-
ible protein phosphorylation, which is controlled by
phosphorylase kinase (PhK) and protein phospha-
tase 1 (PP1). Here we report that lysine acetylation
negatively regulates GP activity by both inhibiting
enzyme activity directly and promoting dephosphor-
ylation. Acetylation of GP Lys470 enhances its inter-
action with the PP1 substrate-targeting subunit, GL,
and PP1, thereby promoting GP dephosphorylation
and inactivation. We show that GP acetylation is
stimulated by glucose and insulin and inhibited by
glucagon. Our results provide molecular insights
into the intricate regulation of the classical GP and
a functional crosstalk between protein acetylation
and phosphorylation.
INTRODUCTION
Glycogen phosphorylase (GP) catalyzes phosphorolytic cleav-
age of glycogen to produce glucose-1-phosphate for glucose-
dependent tissues when body glucose is scarce. GP activity
plays an important role in glucose homeostasis and glycogen
metabolism. Defects in glycogen synthesis and breakdown
in liver, muscle, and other glucose-dependent tissues often
cause glycogen storage diseases (Stegelmeier et al., 1995).
For example, McArdle disease is caused by mutations in muscle
GP, and patients with this disorder are intolerant of exercise
and show early fatigue (Andreu et al., 2007; Tang et al., 2003).
Due to their critical roles in glucose homeostasis, regulations
of glycogen synthase (GS) and GP activities have been exten-
sively investigated in hopes of finding therapeutic strategy for
type II diabetes.CGP was the first allosteric enzyme to be discovered by Carl
and Gerty Cori, who demonstrated that GP existed in two inter-
convertible forms, referred to subsequently as an active a form or
inactive b form, that are regulated by adenosinemonophosphate
(AMP) (Cori and Cori, 1936). GP is activated by the binding of
AMP and IMP, whereas it is inhibited by the binding of ATP
and glucose-6-phosphate (Barford et al., 1991; Barford and
Johnson, 1989). These allosteric controls provide excellent
means of GP activity regulation in response to energy and meta-
bolic status. Moreover, GP activity is tightly regulated by revers-
ible phosphorylation and dephosphorylation. In addition to
allosteric regulation, GP is also regulated by posttranslational
modifications (PTMs) (Johnson, 1992). In fact, GP was also the
first protein discovered to be regulated by reversible protein
phosphorylation (Fischer and Krebs, 1955; Sutherland and
Wosilait, 1955), which exemplifies a signal transduction pathway
by phosphorylation cascades. Under high serum glucose condi-
tions, release of insulin indirectly activates protein phosphatase
1 (PP1), which dephosphorylates Ser-15 and converts the active
a form of GP to the unphosphorylated inactive b form, leading to
the inhibition of glycogen breakdown (Browner and Fletterick,
1992). Conversely, when glucose concentration is low, glucagon
triggers a cascade of signal transduction that activates protein
kinase A (PKA) which phosphorylates and activates phosphory-
lase kinase (PhK), which in turn activates GP by phosphorylating
Ser-15 and leads to increased glycogen breakdown and ulti-
mately higher glucose levels.
PP1 regulates glycogen metabolism by inhibiting GP activity
and activating GS activity. The hepatic glycogen binding subunit
GL is a glycogen-metabolizing scaffold protein that binds to PP1,
glycogen, GS, and GP (Armstrong et al., 1998). GL targets PP1
to glycogen, where it dephosphorylates and inhibits GP, in addi-
tion to dephosphorylating and activating GS, thereby increasing
glycogen synthesis and reducing glucose output (Alemany and
Cohen, 1986). Therefore, the phosphorylation status of GP is
critically regulated by its interaction with GL.
Lysine acetylation has emerged as a common regulatory
mechanism of diverse cellular processes, including metabolism
(Choudhary et al., 2009; Kim et al., 2006; Wang et al., 2010; Zhao
et al., 2010). Acetylation modulates enzymes involved in fattyell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc. 75
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via different mechanisms such as inhibition, activation, and
protein destabilization (Guan and Xiong, 2011; Kim and Yang,
2011). In the present study, we show that acetylation inhibits
GP activity by promoting its dephosphorylation. This is accom-
plished by an acetylation-induced interaction between GP and
the PP1-targeting subunit GL. Our study provides an example
of crosstalk between acetylation and phosphorylation in regula-
tion of a key enzyme of the glycogen metabolism in response to
different physiologic conditions.
RESULTS
Acetylation Negatively Regulates GP Catalytic Activity
In an attempt to profile liver protein acetylation, we previously
enriched acetylated peptides of human liver proteins by affinity
purification (Zhao et al., 2010). Among the many liver acety-
lated proteins identified, two peptides were found to contain
acetylated lysine 470 (K470) and lysine 796 (K796) of GP (see
Figure S1A available online). To confirm GP acetylation, we ex-
pressed Flag-tagged GP in Chang’s liver cells and then treated
cells with nicotinamide (NAM) and trichostatin A (TSA), two
commonly used deacetylase inhibitors that inhibit all four classes
of deacetylases (Xu et al., 2007). GP was found to be acetylated,
and its acetylation was significantly elevated (approximately
2-fold) after NAM and TSA treatment (Figure 1A). Mutation of
both K470 and K796 (GPK2R) dramatically decreased GP acety-
lation (Figure 1B), indicating that K470 and K796 are the major,
if not the sole, acetylation sites in GP.
Next, the functional significance of acetylation in GP catalytic
activity was investigated. For GP assay, we adapted a published
protocol (Jones and Wright, 1970) and confirmed that under the
conditions used in our experiments, the assay was linear to GP
enzyme concentrations and displayed a typical Michaelis-
Menten response to glycogen concentrations (Figures S1B and
S1C). Treatment with deacetylase inhibitors decreased the
specific activity of GP by 75% (Figure 1C), suggesting that GP
activity is negatively regulated by acetylation. Moreover, when
both K470 and K796 of GP were changed to acetylation mimetic
glutamines (GPK2Q), the GPK2Q mutant displayed significantly
lower (about 55%) specific activity than the wild-type. Interest-
ingly, the GPK2Q was no longer inhibited by deacetylase inhibitor
treatment (Figure 1C), indicating that the K470 and K796 in GP
are the primary acetylation sites for its enzymatic inhibition. To
clarify the individual contribution of K470 and K796 acetylation
to GP activity, we generated single lysine to glutamine substitu-
tion on either K470 (GPK470Q) or K796 (GPK796Q). GPK470Q and
GPK796Q had about 30% and 45% less specific activity than
wild-type GP, respectively (Figure 1D), suggesting that acetyla-
tion of either K470 or K796 contributed to GP inhibition. Notably,
unlike GPK2Q, which had negligible response to deacetylase
inhibitor treatment, both GPK470Q and GPK796Q activities were
still partially inhibited by NAM and TSA treatment (Figure 1D),
suggesting that both K470 and K796 acetylation contribute to
GP catalytic activity regulation and that these two acetylation
sites may function additively.
Because GP can form homodimers, we investigated whether
endogenous GP might interfere with our assays by forming het-
erodimers with the transfected mutant GP, and whether the76 Cell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc.mutant GP could dominantly inhibit wild-type GP. In the trans-
fected cells, the ectopically expressed GP was much higher
(about 10-fold) than the endogenous protein GP (Figure S1D),
indicating that endogenous GP should have a negligible effect
on our assay results. Moreover, we purified WT homodimer,
WT-K2R heterodimer, and K2R homodimer and assayed their
catalytic activity. The WT-K2R heterodimer exhibited activity
that was the average of wild-type and K2R homodimers (Fig-
ure S1E), showing that the K2R mutant has no dominant inhibi-
tion on wild-type GP. Together, our results suggest that K470
and K796 are two major acetylation sites in GP responsible for
its inhibition by acetylation. To further test the effect of acetyla-
tion on GP activity and glycogen metabolism, we determined
cellular glycogen content in response to NAM and TSA treat-
ment. Consistent with an inhibitory effect of acetylation on GP
activity, we found that inhibition of deacetylases by NAM and
TSA increased cellular glycogen levels (Figure S1F). Next, we
determined glycogen hydrolysis in cells expressing different
GP mutants. Expression of wild-type GP promoted a faster
glycogen hydrolysis than the GPK2Q mutant (Figure 1E), further
supporting a lower enzymatic activity of the acetylation mimetic
mutant GPK2Q.
GP Acetylation and Activity Are Regulated by Glucose,
Insulin, and Glucagon
Given that glucose concentration is a key factor in GP regulation,
we determined GP acetylation under different glucose concen-
trations. The acetylation level of ectopically expressed GP was
low when cells were maintained in glucose-free medium, and
increased significantly with elevated glucose concentrations
in a dose-dependent manner by as much as 4-fold (Figure 2A),
suggesting that acetylation of GP was upregulated by glucose.
Moreover, acetylation of endogenous GP in L02 human hepato-
cytes was increased by glucose (Figure 2B, Figure S2A). NAM
and TSA treatment of cells cultured in high-glucose medium
could further increase the acetylation level of endogenous GP
(Figure 2B), showing that deacetylation of GP occurs even under
high glucose.
Next, the effect of glucose on GP activity was determined. As
shown in Figure 2C, the activity of wild-type GP was signifi-
cantly inhibited by increasing concentrations of glucose, while
GPK2Q was largely refractory to inhibition by glucose (Fig-
ure 2C). These results suggest that glucose inhibits GP activity
through K470 and K796 acetylation. To further test the function
of acetylation in mediating glucose-induced GP inhibition, we
measured the effect of glucose on GP activity after NAM and
TSA treatment. We hypothesized that since the inhibition of de-
acetylases would increase GP acetylation, high glucose may
not have a significant effect on GP activity in the presence of
deacetylase inhibitors. As expected, glucose increased GP
acetylation and decreased GP activity in the absence of deace-
tylase inhibitors (Figure 2D, lanes 1–4). However, in the pres-
ence of deacetylase inhibitors, glucose had little effect on GP
activity and did not further increase the elevated GP acetylation
(Figure 2D, lanes 5–8). These results further support the notion
that acetylation plays a major role in GP inhibition in response
to glucose.
Both insulin and glucagon are important signals that regulate
GP activity and glycogen metabolism in opposite manners
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Figure 1. GP Activity Is Negatively Regulated by Acetylation
(A) GP acetylation is increased by deacetylase inhibitor. Flag-tagged GP was expressed in Chang’s cells with or without nicotinamide and trichostatin
A (NAM+TSA) treatment. Acetylation levels of Flag bead-purified GP were blotted with pan-anti-acetyllysine antibody (a-AcK). IB and IP denote immunoblotting
and immunoprecipitation, respectively.
(B) K470 andK796 are themajor acetylation sites in GP. Ectopically expressed Flag-GP andGPK2R in Chang’s cells were immunopurified and immunoblottedwith
pan-anti-acetyllysine antibody.
(C) GP catalytic activity is negatively regulated by acetylation. Both wild-type GP and GPK2Q were expressed in Chang’s liver cells with or without NAM+TSA
treatment. Catalytic activity of affinity-purifiedGP proteins was determined and normalized to protein levels. Activity of wild-type GP under no treatment condition
was set as 100%.
(D) The acetylation targets K470 and K796 are important for GP inhibition by the deacetylase inhibitor treatment. GP, GPK470Q, GPK796Q, and GPK2Q were each ex-
pressed in Chang’s liver cells with (hatched bars) or without (solid bars) NAM+TSA treatment as indicated. Specific activity of each purified enzyme was determined.
(E)Wild-type GP degrades glycogen faster than K2Qmutant. Wild-type GP andmutant GPK2Qwere expressed at similar levels in Chang’s liver cells maintained in
regular DMEM medium. The medium was replaced by glucose-free DMEM at time 0, and the glycogen degradation rate was measured.
All error bars represent standard deviation (SD). n = 3 for each experimental group.
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whether these two hormones could regulate GP acetylation. In
L02 human hepatocytes, the acetylation of endogenous GPCwas increased with insulin treatment in time- and dose-depen-
dent manners (Figure 2E, Figure S2B). Moreover, acetylation of
ectopically expressed GP increased within 30 min of insulinell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc. 77
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Figure 2. Regulation of GP Acetylation by Glucose, Insulin, and Glucagon
(A) Glucose increases GP acetylation. Acetylation levels of GP ectopically expressed in Chang’s cells maintained in different glucose concentrations were probed
by anti-acetyllysine antibody.
(B) Glucose and deacetylase inhibitor increase endogenous GP acetylation. Human hepatic L02 cells were treated with various concentrations of glucose and
deacetylase inhibitors as indicated. Endogenous GP was immunoprecipitated with a GP antibody. Acetylation levels of GP were determined by western blot.
(C) Glucose decreases GP activity through acetylation. Relative specific activity of GP (solid bars) and GPK2Q (hatched bars) expressed in Chang’s cells
maintained in different glucose concentrations was determined. Specific activity of GP from glucose-free medium was arbitrarily set as 100.
(D) Deacetylase inhibitor treatment blocks the glucose inhibition on GP activity. Relative specific activities for GP expressed in Chang’s cells maintained in
different glucose concentrations with (hatched bars) and without NAM+TSA treatment (solid bars) were determined.
(E) Insulin and deacetylase inhibitor increase endogenous GP acetylation. Human hepatic L02 cells were treated with increasing concentrations of insulin and
treated with deacetylase inhibitors as indicated. Acetylation of immunoprecipitated endogenous GP was detected by western blot.
(F) Insulin decreases GP activity through acetylation. Flag-GP (solid bars) and Flag-GPK2Q (hatched bars) were expressed in Chang’s cells and treated with
increasing concentrations of insulin. GP acetylation and activity were determined.
(G) Glucagon decreases GP acetylation. Acetylation levels of Flag-GP expressed in Chang’s cells treated with 10 nM glucagon for different time periods
(as indicated) were determined.
All error bars represent standard deviation (SD). n = 3–4 for each experimental group.
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both glucose and insulin. GP acetylation in cells cultured in
the presence of both glucose and insulin was higher than cells
cultured in either glucose or insulin (Figure S2D). Consistent
with the stimulatory effect of insulin on GP acetylation, we found
that insulin inhibited GP activity in a dose-dependent manner
(Figure 2F, lanes 1–5). These effects required K470 and K796,
as the GPK2Q mutant showed little acetylation and its catalytic
activity did not respond to insulin treatment (Figure 2F, lanes
6–10). Contrary to insulin treatment, glucagon decreased GP
acetylation in a time-dependent manner (Figure 2G). Together,
these results suggest that insulin and glucagon may regulate
GP activity by affecting K470 and K796 acetylation.
Acetylation Decreases GP Phosphorylation
It is well-characterized that GP is activated by PhK-mediated
serine phosphorylation at Ser-15 (Nolan et al., 1964). To investi-
gate the mechanism of acetylation in regulating GP activity, we
looked into a possible crosstalk between acetylation and phos-
phorylation by determining GP serine phosphorylation under
different conditions that are known to affect GP acetylation
levels. We found that deacetylase inhibitor treatment increased
GP acetylation and at the same time decreased Ser-15 phos-
phorylation by 70% (Figure 3A). Similar results were observed
when we utilized a panphosphoserine antibody to detect the
GP serine phosphorylation level after NAM and TSA treatment
(Figure S3A). The inverse relationship between endogenous GP
acetylation and phosphorylation in responding to deacetylase
inhibitor was also examined in L02 human hepatocytes and
freshly isolated mouse primary hepatocytes. In both hepato-
cytes, endogenous GP showed a significant increase in acetyla-
tion and a concomitant decrease in Ser-15 phosphorylation
upon NAM and TSA treatment (Figure 3B). Similar results were
also observed in freshly isolated mouse skeletal muscle cells
(Figure S3B). These observations demonstrate that acetylation
negatively regulates GP phosphorylation.
To provide direct evidence that acetylation regulates GP
phosphorylation, we examined GP phosphorylation status
when GP was coexpressed with deacetylases. When GP was
coexpressed with SIRT1 and SIRT2, two cytosolic deacetylases,
an evident decrease in GP acetylation and concomitant in-
crease in GP Ser-15 phosphorylation were observed, with
SIRT2 being more potent in deacetylating GP and increasing
Ser-15 phosphorylation (Figure 3C). Collaborating with these
findings, the catalytic activity of GP was also activated by either
SIRT1 or SIRT2 coexpression. This result indicates a causal role
of acetylation in modulating GP phosphorylation.
To further elucidate the relationship between GP acetylation
and phosphorylation, we determined the effect of deacetylase
inhibitors on the activity of GPS15D, which had Ser-15 replaced
by an aspartic acid and displayed a lower activity (Buchbinder
et al., 1997). Interestingly, the activity of GPS15D mutant was
not inhibited by deacetylase inhibitor treatment, whereas the
wild-type GP was potently inhibited by a similar treatment
(Figure 3D). Of note, glucose still increased the acetylation of
GPS15D mutant (Figure 3E). Therefore, Ser-15 phosphorylation
is not required for high-glucose-stimulated GP acetylation;
rather, acetylation may downregulate Ser-15 phosphorylation
and activity of GP.CBecause of the inhibitory effect of acetylation on phosphoryla-
tion, the above data were unable to show whether acetylation
may directly affect GP activity. To address this question, we
prepared GP with or without acetylation and with or without
phosphorylation. Hyperacetylated GP was obtained by express-
ing Flag-GP in Chang’s liver cells maintained in high-glucose
(25 mM) medium supplemented with NAM and TSA, while hypo-
acetylated GP was obtained by glucose-free medium without
NAM and TSA. The immunopurified GP proteins were treated
with l-phosphatase or PhK in vitro. After verifying both the acet-
ylation and the Ser-15 phosphorylation of GP by western blotting
(right panel, Figure 3F), GP activity was determined. We found
that phosphorylation by GP kinase (PhK) dramatically increased
GP activity regardless of whether GP was hyperacetylated (lane
1 versus lane 2, left panel, Figure 3F) or hypoacetylated (lane 3
versus lane 4). Acetylation did not affect GP activity when GP
was hypophosphorylated (lanes 1 versus lane 3). However,
when GP was hyperphosphorylated, acetylation exhibited an
inhibitory effect onGP in vitro (lane 2 versus lane 4). These results
indicate that acetylation inhibits GP only when it is hyperphos-
phorylated and active.
GP is also regulated by allosteric effect, including activation
of inactive b form by AMP. To explore the effect of acetylation
on allosteric regulation of GP, we determined the activity of
hypo- versus hyperacetylated GP in response to AMP. We found
that AMP induced a similar activation to both the hyperacety-
lated (lane 1 versus lane 1A, 20.5-fold, Figure 3F) and hypoace-
tylated GP (lane 3 versus lane 3A, 20.4-fold) when GP was
hypophosphorylated, indicating that acetylation does not
directly affect allosteric activation of GP by AMP. However,
when GP was fully activated (hypoacetylated/hyperphosphory-
lated), AMP could not activate GP further (lanes 4 versus 4A).
To provide more direct evidence to determine the effect of
acetylation on allosteric regulation, we treated immunopurified
GP with recombinant deacetylase CobB in vitro and measured
its allosteric activation by AMP after confirming the decrease
of acetylation (right panel, Figure 3G). We found that AMP acti-
vated GP equally regardless of the levels of GP’s acetylation
(5.54-fold, 5.58-fold, and 5.50-fold, left panel, Figure 3G). We
therefore conclude that acetylation does not directly affect allo-
steric activation of GP by AMP.
Physiological Stimuli Regulate GP Acetylation-Induced
Dephosphorylation
The notion that acetylation negatively regulates GP-Ser-15
phosphorylation was further pursued by analyzing acetylation
and phosphorylation levels in response to physiological stimuli.
We found that glucose increased GP acetylation and decreased
phosphorylation in a dose-dependent manner (Figure 4A), indi-
cating an inverse relationship between GP acetylation and
phosphorylation. Moreover, insulin treatment increased GP
acetylation and decreased GP phosphorylation (Figure 4B),
whereas glucagon treatment decreased GP acetylation and
increased GP phosphorylation (Figure 4C). A time-dependent
inverse correlation between acetylation and phosphorylation in
GP was observed in response to glucose, insulin, and glucagon
(Figure 4D, Figures S4A and S4B), supporting the notion that
acetylation may inhibit GP phosphorylation. It is worth noting
that glucagon can regulate GP activity through a direct signalingell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc. 79
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Figure 3. Acetylation Decreases GP Ser-15 Phosphorylation
(A) Deacetylase inhibitor treatment inhibits GP phosphorylation. Flag-GP was expressed in Chang’s liver cells and treated with or without NAM+TSA. Acetylation
and GP-Ser-15 phosphorylation levels of Flag-GP proteins were determined by western blot.
(B) Deacetylase inhibitor treatment increases acetylation and decreases phosphorylation of hepatic GP. Human hepatic L02 cells and mouse primary hepato-
cytes were treated with or without NAM+TSA as indicated. Acetylation and Ser-15 phosphorylation of GP proteins were determined by western blot (L02,
#p = 0.0094, n = 3, and ##p = 0.0107, n = 3; primary hepatocytes, #p = 0.0090, n = 3, and ##p = 0.0270, n = 3).
(C) Coexpression of deacetylases reduces GP acetylation and increases GP phosphorylation. Flag-GP was expressed alone or coexpressed with Sirt1 and Sirt2
in Chang’s liver cells as indicated. Acetylation and Ser-15 phosphorylation of affinity-purified GP were measured. Relative specific activities of GP were
determined by normalizing GP activity against GP protein.
(D) GP Ser-15 is required for deacetylase inhibitor-induced GP inactivation. Wild-type GP and GPS15D mutant GP were expressed in Chang’s liver cells, with or
without NAM+TSA treatment. Activities of affinity-purified GP were determined.
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Acetylation Inhibits Glycogen Phosphorylasepathway. Of note, although Ser-15 phosphorylation occurred
rapidly and was evident as early as 30 min after glucagon
treatment, it increased continuously throughout the 4 hr of
experimental duration (Figures 2G and 4D). Thus, it is possible
that deacetylation may not be required for the acute GP phos-
phorylation by glucagon but rather may play a role to maintain
the phosphorylated and active GP in the active state (Figure S7).
We next examined the response of Ser-15 phosphorylation
in GPK2R, the nonacetylatable form of GP, to different glucose
concentrations. Contrary to wild-type GP, which showed
increased acetylation and decreased Ser-15 phosphorylation
by glucose, Ser-15 phosphorylation of GPK2R was largely unaf-
fected by increasing glucose concentrations (Figure S4C),
indicating an essential role of acetylation in regulating Ser-15
phosphorylation. Notably, Ser-15 phosphorylation remained
constitutively high in GPK2R regardless of the glucose concentra-
tions, suggesting that the deacetylated GP favors being
phosphorylated at Ser-15. This notion was supported by the
observation that GPK2Q, the acetylation mimetic mutant, not
only showed a very weak phosphorylation level but that its
phosphorylation was unresponsive to varying glucose concen-
trations (Figure S4D). Similarly, insulin did not influence the
phosphorylation levels of either GPK2Q or GPK2R (Figure S4E).
Collectively, the above data indicate that acetylation of K470
and K796 is required for GP phosphorylation regulation by
glucose and insulin.
To obtain in vivo data to support the inverse relationship
between GP acetylation and Ser-15 phosphorylation, mouse
experiments were performed. Upon feeding, a state that causes
high glucose or high insulin, mouse liver GP acetylation level was
high, whereas the level of Ser-15 phosphorylation was low (Fig-
ure 4E, Figure S4F). After overnight fasting, hepatic GP acetyla-
tion was decreased, while hepatic Ser-15 phosphorylation
was inversely increased. Furthermore, when mice were intra-
peritoneally injected with glucose (1 g/kg), insulin (5 U/kg), or
glucagon (0.2 mg/kg), in line with our observations in vitro,
glucose and insulin injection increased endogenous GP acetyla-
tion and decreased Ser-15 phosphorylation (Figures 4F and 4G,
Figures S4G and S4H). In contrast, glucagon injection decreased
endogenous GP acetylation and increased Ser-15 phosphoryla-
tion in mouse livers (Figure 4H, Figure S4I). Together, these data
indicate an inverse coregulation of GP acetylation and Ser-15
phosphorylation, and the regulation of these two PTMs under
physiological conditions.
Acetylation Increases the GP-PP1a Interaction
After establishing a causal relationship between acetylation and
phosphorylation, a key question is how acetylation modulates(E) The effect of glucose on GP activity but not acetylation depends on Ser-15. GP
of glucose. Acetylation, phosphorylation, and relative activity of GPS15D were det
(F) Effect of acetylation and phosphorylation on GP activity and activation by A
Chang’s liver cells maintained in high-glucose (25 mM) medium supplemente
GP-transfected cells cultured in glucose-free medium without NAM+TSA. The
kinase (PhK) in appropriate buffers for 2 hr. Both phosphatase and kinase were r
activity with (hatched bars) or without AMP (5 mM, solid bars) as indicated. Relati
and lysine acetylation levels were determined by western blotting.
(G) GP allosteric activation by AMP is not affected by acetylation. Flag-GPwas pur
indicated. Relative activity of purified GP was measured in the absence (solid bars
All error bars represent standard deviation (SD). n = 3 for each experimental gro
CGP phosphorylation, which is controlled by the PhK and PP1.
The interaction between GP and PP1 is important for GP
dephosphorylation. As expected, coexpression of PP1a, the
phosphatase that dephosphorylates P-Ser-15 of GP, largely
abolished the inhibitory effect of deacetylase inhibitor on GP
activity (Figure S5A). We thus investigated whether acetylation
affected the PP1a-GP interaction. When PP1a and GP were
coexpressed in Chang’s cells, the interaction between PP1a
and GP was readily detectable (Figure 5A). Interestingly, the
PP1a-GP interaction was increased (by more than 100%) after
deacetylase inhibitor treatment (Figure 5A), suggesting that
acetylation enhances the recruitment of PP1a to GP. Consistent
with a role of acetylation in promoting the interaction between
PP1a and GP, deacetylase inhibitor treatment did not further
increase the interaction between PP1a and GPK2Q (Figure 5B).
To further confirm the function of acetylation in enhancing the
PP1a-GP interaction, we compared the binding of PP1a to GP
and the acetylation mimic GPK2Q mutant. When PP1a and GP
proteins were coexpressed in Chang’s cells, the amount of
PP1a protein coimmunoprecipitated with GPK2Q was about 2-
fold more than that associated with the wild-type GP protein,
suggesting that the acetylation of GPmay enhance its interaction
with PP1a. Consistently, the phosphorylation level of GPK2Q was
about 60% weaker than that of the wild-type GP (Figure 5C).
Moreover, deacetylase inhibitor treatment decreased Ser-15
phosphorylation of GP that was already reduced by PP1a coex-
pression (Figure 5A, Figure S5B). Furthermore, coexpression of
SIRT2 impaired the interaction between GP and PP1a and at
the same time stimulated GP serine phosphorylation (Figure 5D).
Taken together, the above data support a model in which acet-
ylation of K470 and K796 in GP enhances its interaction with
PP1a, thereby resulting in GP dephosphorylation and inactiva-
tion (Figure 7).
K470 Acetylation Increases GP-GL Interaction
The PP1-GP interaction is mediated by GL, a substrate-targeting
subunit of PP1 (Armstrong et al., 1998). To determine whether
the observed PP1a-GP interaction resulted from increased
PP1a-GL, Flag-PP1a and HA-GL were coexpressed in Chang’s
cells, and the interaction between PP1a and GL was determined.
We found that the association between PP1a and GL was not
altered by deacetylase inhibitor treatment (Figure S6A), indi-
cating that acetylation does not regulate interaction between
PP1 and GL. On the other hand, the interaction between GP
and GL was increased upon deacetylase inhibitor treatment (Fig-
ure 6A, lanes 3 and 4). GL binds toGP through its C-terminal 269–
284 residues, and deletion of these five residues in GL diminishes
its interaction with GP (Kelsall et al., 2007; Pautsch et al., 2008).S15D-transfected Chang’s liver cells were treated with different concentrations
ermined. Activity of GP from glucose-free medium was set as 100% arbitrarily.
MP. Hyperacetylated GP was immunoprecipitated from Flag-GP-transfected
d with NAM+TSA. Hypoacetylated GP was immunoprecipitated from Flag-
immunopurified GP was incubated with l-phosphatase (l) or phosphorylase
emoved by washing with PBS, and the treated GP was measured for enzyme
ve enzyme activity was normalized against GP protein. Ser-15 phosphorylation
ified fromChang’s liver cells and then treated for 1 or 2 hr with buffer or CobB as
) or presence of 5 mM AMP (hatched bars) and normalized by protein quantity.
up.
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Figure 4. GP Acetylation and Phosphorylation Are Inversely Regulated by Physiological Stimuli
(A–C) The effect of glucose, insulin, and glucagon on GP acetylation and phosphorylation. Flag-GP-expressing Chang’s cells were treated with different
conditions as indicated. Acetylation and serine phosphorylation of Flag-GP were determined by western blotting.
(D) Time course of glucagon onGP acetylation and phosphorylation. Flag-GP-expressing Chang’s liver cells were treatedwith glucagon (10 nM) for different times
as indicated. Levels of GP acetylation and Ser-15 phosphorylation were determined by western blotting.
(E) Fasting decreases GP acetylation and increases GP phosphorylation in mouse liver. Mice were fasted overnight before sacrifice, and GP proteins were
immunoprecipitated from the liver. Acetylation and Ser-15 phosphorylation levels of GP were determined by western blot (#p = 0.0021, n = 3; ##p = 0.0064, n = 3).
(F and G) Both glucose and insulin increase acetylation and decrease phosphorylation of GP in mouse liver. Glucose (1 g/kg) or insulin (5 U/kg) was intraperi-
toneally injected into overnight-fasted mice. At 30 min postinjection, mice were sacrificed and liver samples were harvested. GP proteins were immunopre-
cipitated from the liver, and acetylation and Ser-15 phosphorylation levels of GP proteins were determined by western blot (glucose, #p = 0.0191, n = 3, and
##p = 0.0013, n = 3; insulin, #p = 0.0021, n = 3, and ##p = 0.0036, n = 3).
(H) Glucagon decreases acetylation and increases phosphorylation of GP in mouse liver. Glucagon (0.2 mg/kg) was intraperitoneally injected into fed mice, and
the mice were sacrificed at 30 min postinjection. GP protein was immunoprecipitated from liver, and acetylation and serine phosphorylation were determined by
western blotting (#p = 0.0200, n = 3; ##p = 0.0100, n = 3).
All error bars represent standard deviation (SD). n = 3 for each experimental group.
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Figure 5. Acetylation Increases GP-PP1a
Interaction
(A) Deacetylase inhibitor treatment enhances GP
binding to PP1a and decreases GP phosphoryla-
tion. Flag-GP was coexpressed with HA-PP1a in
Chang’s liver cells and treated with or without
NAM+TSA. GP coprecipitation with PP1a and
serine15 phosphorylation was determined by
western blot.
(B) Deacetylase inhibitor treatment has no affect
on the interaction between GPK2Q and PP1a. Flag-
GPK2Qwas coexpressedwith HA-PP1a in Chang’s
liver cells, and NAM+TSA treatment was indi-
cated. GPK2Q coprecipitation with PP1a was
determined.
(C) GPK2Q binds more strongly to PP1a than wild-
typeGP. HA-PP1awas coexpressedwith Flag-GP
or Flag-GPK2Q in Chang’s liver cells. PP1a-GP
and PP1a-GPK2Q interactions were detected
by coimmunoprecipitation. Phosphorylation of
GP and GPK2Q were determined by panphos-
phoserine antibody.
(D) Ectopic expression of SIRT2 decreases
PP1a-GP binding and increases GP serine phos-
phorylation. Flag-GP was expressed alone or
coexpressed with HA-PP1a or Myc-SIRT2 in
Chang’s liver cells as indicated; PP1a-GP inter-
action and GP serine phosphorylation level were
determined.
All error bars represent standard deviation (SD).
n = 3 for each experimental group.
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DC5 mutant by deleting the C-terminal
five residue deletion of GL and confirmed that the deletion weak-
ened the binding of GL with GP. Notably, inhibition of deacety-
lases increased the interaction between GL
DC5 and GP to a level
similar to that of wild-type GP (Figure 6A). This result suggests
that the acetylation enhances the GP-GL interaction through
a site in GL that is independent of the C-terminal five residues
in GL. Consistently, when GP
K2R was coexpressed with GL
DC5
in Chang’s cells, virtually no interaction was detected between
them in either the presence or the absence of deacetylase inhib-
itors (Figure S6B). Meanwhile, we characterized another protein,
PTG (protein targeting to glycogen), which also functions as
a molecular scaffold targeting GP to PP1 (Brady et al., 1997),
and investigated whether acetylation regulates GP and PTG
interaction. The result demonstrated that GP-PTG binding could
also be stimulated by NAM and TSA treatment (Figure S6C).
To obtain direct evidence to support a role of acetylation in
promoting GP-GL interaction, we performed in vitro deacetyla-
tion and binding experiments. Hyperacetylated GP was purified
from cells treated with deacetylase inhibitors, and the purified
GP was deacetylated in vitro by incubating with the NAD+-
dependent bacterial deacetylase CobB. We found that CobB
treatment decreased GP acetylation and also reduced the
interaction of GP-GL in a NAD
+-dependent manner (Figure 6B),
providing direct biochemical evidence that acetylation of
GP enhances its interaction with GL. We extended these
experiments in mouse liver. Plasmids encoding epitope-tagged
GP and GL were intravenously injected into mouse tail veins
to express the two proteins in liver. The interaction of theCectopically expressed GP and GL in mouse liver was determined
in response to glucose signal. When glucose (1 g/kg) was in-
jected intraperitoneally into fasted mice, we found that the
hepatic GP-GL interaction was increased significantly (Fig-
ure 6C). As expected, glucose injection indeed increased blood
glucose concentration (Figure S6D). These results further
support the notion that acetylation of GP increases GP-GL inter-
action in vivo.
We next investigated the importance of K470 and K796
acetylation sites in regulating the GP-GL interaction. HA-GL
with Flag-GPK470Q or GPK796Q was coexpressed in Chang’s
cells. As a positive control, deacetylase inhibitors increased
the interaction between wild-type GP and HA-GL (Figure 6D,
lanes 3 and 4). In contrast, a similar treatment did not increase
the interaction between Flag-GPK470Q and GL, and the mutant
GPK470Q displayed a stronger interaction with GL than the wild-
type GP (Figure 6D, lanes 6 and 7). On the other hand, the
binding between GPK796Q and GL was increased by NAM+TSA
treatment, and GPK796Q showed a basal GL interaction similar
to the wild-type protein (Figure S6E). These results suggest
that the acetylation-enhanced interaction between GP and GL
is predominantly mediated by K470, but not K796. We per-
formed iTRAQ mass spectrometry analyses to quantify GP
K470 acetylation. Our results showed that as much as 50% of
GP was acetylated at K470 in this assay and that inhibition of
deacetylases resulted in an increase in the ratio of acetylated
K470 versus unacetylated K470 from roughly 1:1 to 2:1 (Fig-
ure 6E, Figures S6F–S6I), suggesting that a substantial fraction
of K470 in GP is acetylated in the cell.ell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc. 83
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Figure 6. Acetylation Increases GP-GL
Interaction
(A) Acetylation enhances GP-GL interaction. Flag-
GP was transfected into Chang’s liver cells either
alone or with HA-tagged GL or GL
DC5. NAM+TSA
treatment was indicated. GP-GL and GP-GL
DC5
interactions were determined by coimmunopreci-
pitation.
(B) Deacetylation of GP decreases GP-GL inter-
action in vitro. Flag-GP was expressed in HEK293
cells in the presence of deacetylase inhibitor,
and HA-GL was separately expressed. Both
proteins were affinity purified. Flag-GP was de-
acetylated with purified bacterial deacetylase
CobB in vitro as indicated. In vitro binding
between Flag-GP and HA-GL was performed.
Acetylation level of Flag-GP and the amount of
HA-GL coprecipitated by Flag-GP were deter-
mined by western blot.
(C) Glucose increases GP-GL interaction in vivo.
Human Myc-GP and HA-GL plasmids were intra-
venously injected into mice. The injected mice
were fasted overnight and then intraperitoneally
injected with glucose (1 g/kg). The mice were
sacrificed at 30 min postinjection. GP and GL
proteins expressed in the injected mouse liver
were immunoprecipitated by Myc beads for Myc-
GP. The amount of GP and coprecipitated GL
proteins was measured, and the GL/GP ratio was
calculated.
(D) K470 is required for deacetylase inhibitors to
stimulate the GP-GL interaction. Flag-GP and
Flag-GPK470Q were transfected in Chang’s liver
cells, either alone or with HA-tagged GL. Cells
were treated with or without NAM+TSA. GP-GL
interactions were determined by coimmunopreci-
pitation.
(E) Quantification of GP K470 acetylation. Acety-
lation levels of K470 of GP expressed in Chang’s
liver cells treated with or without NAM+TSA were
quantified by iTRAQ.
(F and G) K470 in GP is required for regulation of
GP-GL interaction by glucose and insulin. Flag-GP
and Flag-GPK470Q were transfected in Chang’s
liver cells, either alone or with HA-tagged GL. Cells
were treated with or without glucose (F) or insulin
(G). GP-GL interactions were determined by
coimmunoprecipitation.
All error bars represent standard deviation (SD).
n = 3–4 for each experimental group.
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lated by physiological stimuli, we determined the interaction
between GL with either wild-type or K470Q mutant GP in
response to glucose concentration and insulin stimulation. We
found that the GP-GL interaction was increased by approxi-
mately 100% after switching from glucose-free medium to
25 mM glucose medium (Figure 6F). However, a similar glucose
switch did not affect the interaction between GPK470Q and GL.
Furthermore, insulin stimulated the interaction between the
wild-type GP, but not GPK470Q, and GL (Figure 6G). These results
support the notion that GP-GL interaction is regulated by K470
acetylation in response to nutrient and hormonal signals.84 Cell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc.DISCUSSION
Following the initial discovery of histone acetylation (Allfrey et al.,
1964; Phillips, 1963), extensive studies over the last four
decades have identified not only the enzymes that catalyze
reversible acetylation, the protein lysine acetyltransferases
(KATs, formerly termed histone acetyltransferases, HATs), and
deacetylases (commonly known as histone deacetylases, or
HDACs) but also many nonhistone substrates. Until relatively
recently, nearly all well-characterized acetylation substrates
were nuclear proteins, including transcription factors and core-
gulators (Yang and Seto, 2008). Recent studies, in particular
Figure 7. Acetylation Negatively Regulates
GP Activity by Promoting the Binding of
Phosphatase and the Dephosphorylation
of GP
The acetylation of GP is stimulated by glucose and
insulin and inhibited by glucagon. The acetylation
enhances the binding of GL subunit to GP and
dephosphorylation of GP by PP1.
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2009) and proteomic studies of acetylomes in different organ-
isms (Guan and Xiong, 2011; Kim and Yang, 2011), have re-
vealed important and broad roles of acetylation in the regulation
of nontranscriptional processes, including especially the regula-
tion of metabolic enzyme activity. In this study we have uncov-
ered an important function of acetylation in the regulation of
GP, the key enzyme in glycogen breakdown. Our study has
gained new molecular insights into the regulation of this exten-
sively investigated and historically significant enzyme.
Crosstalk between different protein PTMs, such as phosphor-
ylation-targeted protein ubiquitylation (Hunter, 2007), plays an
important role in coordinating and connecting different cellular
processes. As metabolism needs to respond to a variety of intra-
and extracellular conditions such as cell growth signals and
nutrient availability, metabolic enzymes, which have now been
found to be frequently modified by acetylation, are expected to
be subject to such crosstalk regulation between acetylation
and other type of PTMs. We have demonstrated recently that
acetylation of phosphoenolpyruvate carboxykinase (PEPCK1),
a rate-limiting enzyme in gluconeogenesis, promotes its associ-
ation with UBR5/EDD1 HECT E3 ligase and thus its degradation
in the presence of high glucose (Jiang et al., 2011). The current
study adds another distinct example—promoting protein
dephosphorylation by facilitating the recruitment of a phospha-
tase—of crosstalk between acetylation and phosphorylation.
Our results support a model in which acetylation of GP modu-
lates its phosphorylation status by enhancing GP’s binding
with the GL subunit of PP1 phosphatase, thereby stimulating
GP dephosphorylation by PP1 and inhibiting GP activity (Fig-
ure 7). Although it remains to be elucidated how the acetylation
of GP, mostly on K470, facilitates the binding of GL to GP, we
speculate that controlling protein-protein interaction by acetyla-
tion could be a broad mechanism for acetylation to regulate
activities of other metabolic enzymes or proteins.
Beside reversible phosphorylation, another remarkable
feature of GP regulation is its interaction with several allosteric
effectors, including glucose and AMP, and regulation by
hormones, such as insulin and glucagon, thereby allowing cells
to integrate different cellular conditions and energy status to
the regulation of GP. The finding that GP acetylation and activity
are controlled by glucose, insulin, and glucagon places acetyla-
tion downstream of these physiological stimuli. Binding of
glucose shifts GP in liver from a more relaxed and thus active
state (R) to a tense and less active state (T). As a result, low
glucose would lead to decreased glucose binding and higher
GP activity, resulting in an increased production of glucose
from glycogen. Under such low glucose conditions, GP is hypo-
acetylated in the cell and its interaction with GL (hence PP1) isCweakened, which in turn would increase GP Ser-15 phosphory-
lation and activity (Figure 7). Conversely, in cells with high
glucose concentration, GP is hyperacetylated and the acetyla-
tion enhances GP’s binding with GL and thus PP1, leading to
decreased Ser-15 phopshorylation and activity of GP and even-
tually reduced glycogen degradation. Therefore, it appears that
high glucose can downregulate GP activity by two different
mechanisms: a conformational change by the direct binding of
glucose and acetylation-mediated dephosphorylation. It will be
important to determine whether these two regulations operate
separately or sequentially, and whether GP conformational
change brought by the initial glucose binding facilitates the
acetylation.
The role of acetylation in recruiting PP1 is clearly consistent
with the inverse correlation between acetylation and phosphory-
lation of GP. Glucagon can induce a direct signaling pathway to
phosphorylate and activate GP in a manner independent of
acetylation. However, we speculate that the decrease of GP
acetylation induced by glucagon may contribute to the magni-
tude and duration of GP activation in response to glucagon.
Glucagon stimulates GP by activating the GP kinase via the
classical phosphorylation cascade and also by dissociating GP
phosphatase via acetylation (Figure S7). It should be noted that
acetylation appears to have no direct role in GP allosteric activa-
tion by AMP, although AMP cannot further activate GP when GP
is fully active. Although the precisemechanism bywhich glucose
regulates GP acetylation remains to be elucidated, using
acetylation machinery to control GP adds another layer of
regulation and thus lends cells further versatility in integrating
multifaceted signaling pathways and nutrient conditions to this
enzyme that is not only central to the glycogen metabolism,
but is also interlocked with multiple energy metabolic pathways.
EXPERIMENTAL PROCEDURES
Mouse Liver Collection and Primary Hepatocytes
and Muscle Cell Isolation
Male BALB/cmice (4–6 weeks old, 20–25 g) were divided into two groups, fed,
and overnight fasted. Fasting started from late afternoon and lasted for 16 hr
before experiments. The fasted mice were further subdivided into glucose-
and insulin-treated groups, and the fed mice were treated with glucagon.
Mice blood glucose levels were measured by Accu-Chek Active Blood
Glucose Meter (Roche). At 30 min postinjection, mice were sacrificed and liver
samples were harvested. In addition, mouse primary hepatocytes and muscle
cells were isolated. Please refer to the Supplemental Experimental Procedures
for detailed information. Animal experiments were performed at Fudan Animal
Center in accordance with the animal welfare guidelines.
Glycogen Content Measurement
Cells were washed twice and then lysed with supersonic. The cell lysate in 1ml
PBS (pH 4.8) was heated at a boiling point for 10 min to liberate storedell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc. 85
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centrifugation for 15 min at 13,000 rpm, 4U amyloglucosidase (Sigma) was
added into the supernatant. The resulting mixture was incubated for 1 hr at
50C and followed by boiling for 10 min at 99C. The cell lysate without
amyloglucosidase was included as a control. Subsequently, the glycogen
content was colorimetrically measured using a glucose assay kit (GAGO20,
Sigma). The mixtures were incubated for 30 min at 37C, and absorbance at
540 nm was measured by using a UV/Visible spectrophotometer reader
(Ultrospec 3100 pro, Amersham Biosciences).
iTRAQ Quantification
Flag-GP proteins were expressed in Chang’s liver cells and quantified by
iTRAQ following the method modified according to Zhao (Zhao et al., 2010).
GP was immunopurified from cells untreated or treated with NAM and TSA,
resolved on 10% SDS-PAGE, and stained by Coomassie blue and sliced.
The dye of gel slice was removed by soaking with 50 mM NH4HCO3 and
50% acetonitrile, followed by water wash twice and removing water by
acetonitrile. The gel was dried and digested in 100 ml 50mM NH4HCO3 with
trypsin (trypsin:protein at 1:30) at 37C overnight. The trypsin-treated peptides
were extracted by a volume containing 50% acetonitrile and 0.1% trifluoro-
acetic acid (TFA) and then followed by vacuum dry. Standard control peptides
and GP samples were separately labeled with different iTRAQ-labeling
reagents (ABI) as indicated in Table S1 and then subjected to LTQ-OrbiTrap
MS analysis. Quantification of peptides was calculated by comparing relative
intensity of the iTRAQ tags.
Cell Treatment
TSA (0.5 mM) and NAM (5 mM) were added to the culture medium 18 and 6 hr
before cell harvest, respectively. Glucose-free medium was prepared with
DMEM base (GIBCO, #11966) and supplemented with glucose (Sigma), insulin
(Sigma), and glucagon (Sigma) of different concentrations as indicated.
Glucose, insulin, and glucagon treatments were carried out by culturing cells
in DMEM medium for 24 hr before the desired medium was used to replace
DMEM medium.
Glycogen Phosphorylase Activity Assay and CobB Treatment
Flag-tagged proteins were expressed in Chang’s liver cells, eluted by Flag
peptides (Gilson Biochemical), and measured using the method of Jones
and Wright (Jones and Wright, 1970). The GP activity assay consists of
50 mM sodium glycerol-phosphate (pH 7.1), 10 mM potassium phosphate,
5 mM MgCl2, 0.5 mM NAD
+, 1 mM DTT, 1.6 unit phosphoglucomutase, 1.6
unit glucose-6-phosphate dehydrogenase, and 0.2% glycogen in a total
volume of 0.3 ml. The reaction was started by adding GP into the volume
and assayed at 25C. The reaction was monitored by measuring the increase
of fluorescence (excitation 350 nm, emission 470 nm, HITACHI F-4,600 fluo-
rescence spectrophotometer) for NADH generation.
CobB deacetylation treatment was performed by using a method modified
elsewhere (Hallows et al., 2006). CobB was expressed in E. coli, purified
with nickel beads, and stored at 80C in 10%glycerol. The CobBdeacetylation
assay buffer consists of 40mMHEPES (pH 7.0), 6mMMgCl2, 1mMNAD
+, and
n1 mM DTT in a total volume of 0.1 ml. The reaction was started by adding
10 mg CobB and GP into the volume and was assayed at 37C for 1 hr.
l-Phosphatase and Phosphorylase Kinase Treatment
Flag-GP was ectopically expressed in Chang’s liver cells and immunoprecip-
itated by Flag beads. Subsequently, the bead-linked GP was washed by
PBS (pH 7.4) three times before being treated with phosphatase and kinase
(PhK). The l-phosphatase assay consists of NEBuffer Pack for Protein
MetalloPhosphatases (50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Brij
35 [pH 7.5]) and 1 mM MnCl2 in a total volume of 0.4 ml. The reaction was
started by adding 50 units lambda protein phosphatase (#P0753S, NEB) and
GP into the volume and assayed at 30C for 2 hr by shaking. The PhK reaction
assay consists of 41 mM glycerophosphate, 41 mM Tris, 0.2 mM CaCl2, 3 mM
ATP, MgCl2 (pH 8.2). Reaction was started by adding 2U PhK (#P2014, Sigma)
and GP into the volume and assayed at 30C for 2 hr by shaking. The reaction
was terminated by washing the beads three times by PBS and eluting by Flag
peptide, and the activity was determined by fluorescence spectrophotometer
(Cohen, 1973; Shenolikar et al., 1979).86 Cell Metabolism 15, 75–87, January 4, 2012 ª2012 Elsevier Inc.In Vitro Binding
Flag-GP purified by Flag beads was subject to in vitro deacetylation by CobB
before it was mixed with purified HA-GL. The binding was allowed in 4
C for
4 hr before the beads were washed three times by PBS. Proteins on beads
were denatured by SDS loading buffer and detected by western blot.
Statistical Analysis
Statistics were performed with a two-tailed unpaired Student’s t test. All data
shown represent the results obtained from triplicated independent experi-
ments with standard deviations (mean ±SD). The values of p < 0.05 were
considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.12.005.
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